Skip to main content

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

Written by Customer Service on . Posted in Public Companies.

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers about the use of Quell for their patients with knee pain.
About one-quarter of U.S. adults suffer from frequent knee pain, which limits function, decreases mobility, impacts sleep and reduces quality of life.  Chronic knee pain is typically treated with oral non-steroidal anti-inflammatory drugs and occasionally prescription opioids. These medications have side effects and, in the case of opioids, may lead to addiction.  Surgery is an effective option for some individuals with chronic knee pain.Transcutaneous electrical nerve stimulation (TENS) is a safe, non-invasive pain relief option, that has been used by physicians, physical therapists, and other health care professions for decades to treat chronic pain.  Quell is the only true wearable TENS device.  It is well suited to chronic knee pain because it is worn just below the knee, is not much larger than a credit card, and is comfortable enough to use 24/7.  Quell is the only TENS device with specific FDA 510(k) clearance for use while sleeping.  According to the Company’s Quell Health Cloud™, regular Quell users with knee pain wear their device for 10 hours a day and 40% use it while sleeping.  Quell has been commercially available over-the-counter since 2015.  The most recent version, Quell 2.0, was launched in late 2018 and represents the most advanced TENS technology on the market.  Key features include:Only TENS device powered by a proprietary neurostimulation microchipPrescription strength nerve stimulationTherapy Autopilot™ automatically controls and personalizes nerve stimulationAdvanced power management requires battery recharging only once or twice a weekControlled and enhanced by the industry leading Quell Relief mobile appDetects and compensates for changes in the weather that may aggravate painDigital health enabled – objectively tracks sleep, activity and gait and user reported painCovered by 14 U.S. patentsQuell is available to consumers at QuellRelief.com.  Veterans may obtain Quell through their VA hospital (contact customercare@quellrelief.com for information).About NeuroMetrix

NeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter. The Company maintains an active, industry-leading R&D program. For more information, visit NeuroMetrix.com.NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.comSource: NeuroMetrix, Inc.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae1bfdb-f6bd-43e6-8cea-696c3925150d

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.